Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 13, 2023

BUY
$27.8 - $45.35 $139,000 - $226,750
5,000 New
5,000 $217,000
Q4 2022

Feb 13, 2023

BUY
$41.27 - $98.62 $206,350 - $493,100
5,000 New
5,000 $226,000

Others Institutions Holding MRTX

About Mirati Therapeutics, Inc.


  • Ticker MRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,609,800
  • Description
  • Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...
More about MRTX
Track This Portfolio

Track Fishman Jay A LTD Portfolio

Follow Fishman Jay A LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fishman Jay A LTD, based on Form 13F filings with the SEC.

News

Stay updated on Fishman Jay A LTD with notifications on news.